AstraZeneca PLCAZN:LSE

82.50 / 2.08%
Close in GBXToday's changeShares traded1 year changeBeta
As of Apr 23 2014 17:14 BST.Data delayed by at least 15 minutes.

Income statement in USD

Year on year AstraZeneca PLC's revenues fell 8.09% from 27.9730bn to 25.7110bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 6.2400bn to 2.5560bn, a 59.04% decrease. View full income statement

Gross margin79.94%
Net profit margin10.00%
Operating margin14.44%
Return on assets4.70%
Return on equity10.89%
Return on investment6.49%

Growth rates in USD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped 1.75% and 58.71%, respectively. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.

Div yield(5 year avg)0.09%
Div growth rate (5 year)6.43%
Payout ratio (TTM)136.89%
EPS growth(5 years)-13.4583
EPS (TTM) vs
TTM 1 year ago

Cash flow in USD

In 2013, AstraZeneca PLC increased its cash reserves by 18.42%, or 1.3990bn. The company earned 7.4000bn from its operations for a Cash Flow Margin of 28.78%. In addition the company used 2.8890bn on investing activities and also paid 3.0470bn in financing cash flows. View full cash flow statement

Cash flow per share3.39
Price/Cash flow per share11.72
Book value per share10.98
Tangible book value per share-1.3259

Balance sheet in USD

AstraZeneca PLC has a Debt to Total Capital ratio of 30.85%, a lower figure than the previous year's 39.65%. View full balance sheet

Current ratio1.27
Quick ratio1.15
Total debt/total equity0.4468
Total debt/total capital0.3085
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.